Literature DB >> 10698713

Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.

N R Leslie1, A Gray, I Pass, E A Orchiston, C P Downes.   

Abstract

The tumour suppressor protein, PTEN (phosphatase and tensin homolog deleted on chromosome 10), is a phosphatase that can dephosphorylate tyrosine-containing peptides, Shc, focal adhesion kinase and phosphoinositide substrates. In cellular assays, PTEN has been shown to antagonize the PI-3K-dependent activation of protein kinase B (PKB) and to inhibit cell spreading and motility. It is currently unclear, however, whether PTEN accomplishes these effects through its lipid- or protein-phosphatase activity, although strong evidence has demonstrated the importance of the latter for tumour suppression by PTEN. By using a PTEN G129E (Gly(129)-->Glu) mutant that has lost its lipid phosphatase activity, while retaining protein phosphatase activity, we demonstrated a requirement for the lipid phosphatase activity of PTEN in the regulation of PKB activity, cell viability and membrane ruffling. We also made a small C-terminal deletion of PTEN, removing a putative PDZ (PSD95, Dlg and ZO1)-binding motif, with no detectable effect on the phosphatase activity of the protein expressed in HEK293 cells (human embryonic kidney 293 cells) assayed in vitro. Surprisingly, expression of this mutant revealed differential requirements for the C-terminus in the different functional assays. Wild-type and C-terminally deleted PTEN appeared to be equally active in down-regulating PKB activity, but this mutant enzyme had no effect on platelet-derived growth factor (PDGF)-induced membrane ruffling and was only partially active in a cell viability assay. These results stress the importance of the lipid phosphatase activity of PTEN in the regulation of several signalling pathways. They also identify a mutation, similar to mutations that occur in some human tumours, which removes the effect of PTEN on membrane ruffling but not that on PKB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10698713      PMCID: PMC1220919     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  47 in total

Review 1.  Structure and function of phosphoinositide 3-kinases.

Authors:  M P Wymann; L Pirola
Journal:  Biochim Biophys Acta       Date:  1998-12-08

Review 2.  TRP trapped in fly signaling web.

Authors:  C Montell
Journal:  Curr Opin Neurobiol       Date:  1998-06       Impact factor: 6.627

3.  TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

Authors:  D M Li; H Sun
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

4.  The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells.

Authors:  F B Furnari; H J Huang; W K Cavenee
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

5.  High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice.

Authors:  A Suzuki; J L de la Pompa; V Stambolic; A J Elia; T Sasaki; I del Barco Barrantes; A Ho; A Wakeham; A Itie; W Khoo; M Fukumoto; T W Mak
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

6.  Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.

Authors:  D Haas-Kogan; N Shalev; M Wong; G Mills; G Yount; D Stokoe
Journal:  Curr Biol       Date:  1998-10-22       Impact factor: 10.834

7.  Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN.

Authors:  V Stambolic; A Suzuki; J L de la Pompa; G M Brothers; C Mirtsos; T Sasaki; J Ruland; J M Penninger; D P Siderovski; T W Mak
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.

Authors:  M A Davies; Y Lu; T Sano; X Fang; P Tang; R LaPushin; D Koul; R Bookstein; D Stokoe; W K Yung; G B Mills; P A Steck
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

9.  Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK.

Authors:  T Bondeva; L Pirola; G Bulgarelli-Leva; I Rubio; R Wetzker; M P Wymann
Journal:  Science       Date:  1998-10-09       Impact factor: 47.728

10.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

View more
  29 in total

1.  PTEN controls tumor-induced angiogenesis.

Authors:  S Wen; J Stolarov; M P Myers; J D Su; M H Wigler; N K Tonks; D L Durden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Down-regulation of PTEN expression due to loss of promoter activity in human hepatocellular carcinoma cell lines.

Authors:  Dong-Zhu Ma; Zhen Xu; Yu-Long Liang; Jian-Ming Su; Zeng-Xia Li; Wen Zhang; Li-Ying Wang; Xi-Liang Zha
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

3.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

4.  Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions.

Authors:  N R Leslie; D Bennett; A Gray; I Pass; K Hoang-Xuan; C P Downes
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

5.  Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy.

Authors:  James A McCubrey; Melissa L Sokolosky; Brian D Lehmann; Jackson R Taylor; Patrick M Navolanic; William H Chappell; Stephen L Abrams; Kristin M Stadelman; Ellis W T Wong; Negin Misaghian; Stefan Horn; Jörg Bäsecke; Massimo Libra; Franca Stivala; Giovanni Ligresti; Agostino Tafuri; Michele Milella; Marek Zarzycki; Andrzej Dzugaj; Francesca Chiarini; Camilla Evangelisti; Alberto M Martelli; David M Terrian; Richard A Franklin; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2008-02-21

6.  TPIP: a novel phosphoinositide 3-phosphatase.

Authors:  S M Walker; C P Downes; N R Leslie
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

7.  Retinal degeneration triggered by inactivation of PTEN in the retinal pigment epithelium.

Authors:  Jin Woo Kim; Kyung Hwa Kang; Patrick Burrola; Tak W Mak; Greg Lemke
Journal:  Genes Dev       Date:  2008-11-07       Impact factor: 11.361

8.  A limited role for PI(3,4,5)P3 regulation in controlling skeletal muscle mass in response to resistance exercise.

Authors:  D Lee Hamilton; Andrew Philp; Matthew G MacKenzie; Keith Baar
Journal:  PLoS One       Date:  2010-07-16       Impact factor: 3.240

Review 9.  PTEN function: how normal cells control it and tumour cells lose it.

Authors:  Nick R Leslie; C Peter Downes
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

10.  Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity.

Authors:  Juxiang Cao; Jennifer Schulte; Alexander Knight; Nicholas R Leslie; Agnieszka Zagozdzon; Roderick Bronson; Yefim Manevich; Craig Beeson; Carola A Neumann
Journal:  EMBO J       Date:  2009-04-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.